View in EDS

Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].

Saved in:
Bibliographic Details
Title: Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].
Authors: O'Meara TA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Burstein HJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: Hal_burstein@dfci.harvard.edu.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Apr 07. Date of Electronic Publication: 2026 Apr 07.
Publication Type: Published Erratum
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41951458
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22O'Meara+TA%22">O'Meara TA</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Burstein+HJ%22">Burstein HJ</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: Hal_burstein@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2026 Apr 07. <i>Date of Electronic Publication: </i>2026 Apr 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41951458
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2026.02.001
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: O'Meara TA
      – PersonEntity:
          Name:
            NameFull: Burstein HJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 04
              Text: 2026 Apr 07
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1